| | AUGUST 20248IN FOCUSE delman has appointed Xiaoyan Wang as its new health lead for China. This role is newly formed and bolsters its leadership offering through the partnership with Judy Wang, senior advisor, health, and Olivia Zhang, vice president, China Integrated Health. Wang will be tasked with building out the company's vision for the health sector, integrating its teams across disciplines to provide specialist, strategic solutions for its clients' challenges.Wang has nearly 25 years of pharmaceutical and marketing experience, spanning across consumer health, medical communications, and branding, advertising and digital innovation. Her prior agency roles have seen her build up competent teams starting from zero and achieving rapid revenue growth, establishing best-in-class healthcare solutions in China. She has also worked with many of the top life sciences companies. Wang has a keen personal interest in public health, believing that effective and empathetic communications represent a major opportunity to improve health outcomes for everyone.Will Collie, Edelman's vice chair of health in Asia Pacific, states: "Wang has solid business management skills and market development capabilities, and her joining is undoubtedly a great addition to Edelman. Importantly, Wang's track record of working with international health brands will be of significant importance to clients in China."Collie said that, "Edelman's internationally connected business and communications consulting teams will be a key differentiator in Edelman's approach to serving clients in the health sector. Wang completes our efforts to have senior leaders in every major market across Asia Pacific. We believe she will continue to bring her professional strengths into full play in the future and strive to enhance Edelman's integrated communication capabilities in the healthcare field, expanding business possibilities".Wang told, "The healthcare industry is currently undergoing a period of great change, as we face challenges and opportunities such as pressure on drug prices, increased regulation, and accelerated innovation.""In this period of transition, I'm delighted to join Edelman and provide health clients with strategic solutions that enhance health outcomes. I also look forward to contributing to Edelman's continuous development of the health sector," she added. EDELMAN APPOINTS XIAOYAN WANG AS NEW HEALTH LEAD FOR CHINA
< Page 7 | Page 9 >